## **NEUROBLASTOMA UK**
Charity Commission reference number 326385
## **REPORTS AND FINANCIAL STATEMENTS**
For the year ended 31 December, 2022
Page 1
**NEUROBLASTOMA UK**
**REPORT AND FINANCIAL STATEMENTS** For the year ended 31 December, 2022
|Trustees’ annual report
Independent Examiner’s Report
Statement of financial activities
Balance sheet
Notes to the financial statements|**CONTENTS**
**Page**
3-6
7
8
9
10-13|
|---|---|
Page 2
## **TRUSTEES’ ANNUAL REPORT for the year to 31 December, 2022**
The Trustees present their report with the financial statements of the charity for the year ended 31 December, 2022. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the charity also reports in accordance with the Charity Commission for England and Wales’ guidance on public benefit and the Charities Act 2015.
## **Section A**
## **Reference and administrative details**
Charity Name NEUROBLASTOMA UK Registered Charity Number 326385 Registered Address 7/14 Great Dover Street, London SE1 4YR Trustees who manage the charity: Tony Heddon (Chair) Carolyn Jackson (Secretary) Malcolm Dean (Treasurer) Zara Aitchison Ruby Dickens Keith Holmes Jane Morris Andy Pearson Monica Proctor Stephen Smith Debbie Tweddle Faye Watts Kate Wheeler Alastair Whitington (resigned December 2022)
Independent Examiner Haines Watts, Statutory Auditor, 3[rd] Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ Bankers Barclays Bank PLC, Newmarket, LE87 2BB
## **Public Benefit Requirement**
The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.
## **Section B Structure, governance and management**
## **Governing Document**
The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and is a registered Charity number 326385.
## **Recruitment and appointment of new trustees**
Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustee on the recommendation of existing Medical Trustees.
## **Risk Management**
Trustees have considered the major risks to which the charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the
Page 3
impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.
## **Section C Objectives and activities**
## **Objectives and aims**
The object of the Charity is to provide relief for children suffering from Neuroblastoma, and to achieve this, it raises funds for medical research into improving both diagnosis and treatment of the disease. The Charity also offers an opportunity for parents to give each other mutual help, support and comfort.
## **Policy on Grant-making**
Trustees invite applications for grant award by public advertisement, typically on the Charity’s website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity’s Scientific Advisory Board (SAB). Applications are first considered by the Charity’s SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB’s advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity’s unrestricted fund or appropriate restricted fund.
## **Section D Achievements and performance**
## **Charitable activities**
Having completed our bi-annual grant round the previous year, there we were few additional research grants allocated. However, we did fund two grants at Southampton hospital
Dr Jinhui Gao - Investigating the role of Enhancer of Zeste homolog 2 and Natural killer cells in neuroblastoma
Dr Rob Ewing - Looking at how the Zika virus kills Neuroblastoma cells? A potential new oncolytic virotherapy for Neuroblastoma
With the on-going delays through COVID, all the 2019 grants received no cost extensions having the effect of lengthening the time we will hold onto these liabilities before payment
- As part of our our 40th anniversary fundraising activity, our key activities included:
- A comedy night hosted by our Patrons Alan Carr and Angellica Bell at The Rose Theatre in Kingston raised £11,400. Our huge thanks to Alan and Angellica for organising the event and to Off The Kerb Productions.
- We celebrated our anniversary with a special reception in London, which included an art exhibition, online auction and prize draw. The event brought together clinicians, researchers, supporters, charity partners and families affected by neuroblastoma, and raised £18,778.98.
- We launched a range of 40th anniversary merchandise, including pin badges, keyrings, branded sportswear, bottles and bags.
- We worked with Beads of Courage to provide funding for 40 Siblings packs at no cost to the families. The Sibling programme is designed to support and recognise siblings of children with a serious or lifethreatening illness.
We launched our first children’s design competition for our 2022 Christmas card range. The winning designs were by Lucy, aged 13 and Esme, aged 4 who sadly lost family members to neuroblastoma. and helped to raise £975.
As part of Childhood Cancer Awareness Month in September, we launched our Glow Gold event, encouraging supporters to light a Neuroblastoma UK candle and remember all the children and families affected by neuroblastoma. This new initiative raised over £500.
We worked with a number of corporate partners in 2022, who took part in, or organised, a number of a new fundraising events throughout the year. A total of nearly £20,000 was raised by companies including Banks Group, who chose us as their Charity of the Year partner, and Metis Consultants through their Land's End to
Page 4
John o’ Groats challenge. We also launched a new charity video thanks to pro-bono support from Obrizum Media, featuring interviews with researchers and families affected by neuroblastoma. We are also grateful to 3B Digital for their ongoing pro-bono support across our digital channels.
We had our biggest London Marathon team to date in 2022 due to roll over places from the cancelled 2020 event. Our team of 10 runners raised just under £18,000.
We welcomed our third member of paid staff as part of our continued growth and focus on individual giving, community fundraising and challenge events, in a key role of Public Fundraising Manager. Although we saw a drop in income for this area in 2022, this was impacted by reduced staffing resources during the year. With a new Philanthropy and Partnerships Manager role planned for 2023 and a return to full team capacity, we look forward to seeing significant growth in 2023. New initiatives are planned including a new gaming stream consisting of a weekly lottery
We welcomed TV and radio presenter Angellica Bell and Charlie Moore, neuroblastoma survivor and Team GB Paralympian as our new Patrons for 2022. With their passion and personal connection to our cause, alongside our existing Patrons Alan Carr and Scott Mills, we can raise awareness of neuroblastoma to a wider audience.
We continued to distribute our free “Parents Guide to Neuroblastoma” and our factsheet “Treatment options for relapsed or refractory high risk neuroblastoma”, online and in print. Both items were updated and reprinted in 2022, in collaboration with Children’s Cancer and Leukaemia Group. Our webpage was visited nearly 800 times with nearly 300 downloads. We aim to continue to support print costs for the Parent’s Guide in 2023.
## **Section E Financial Review**
## **Reserves Policy**
The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust’s objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2022 was £72,191 (2021 £622,454).
## **Investment Policy**
The Trustees’ intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised.Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.
## **Statement of Trustees Responsibilities**
The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom Generally Accepted Accounting Practice (United Kingdom Standards and applicable law). The financial statements are required by law to give a true and fair view of the state f affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP (FRS102)
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.
The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the charity and to enable them to ensure that the financial statements comply with the
Page 5
Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Approved by the Trustees at a Zoom meeting on 21 July, 2022
Signed on their behalf and with their approval by:
MR T HEDDON Chair
MR M DEAN Trustee and Treasurer
Page 6
## _**Independent Examiner’s Report to the Trustees of Neuroblastoma UK**_
I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2022.
## _**Respective responsibilities of Trustees and Examiner**_
The charity’s trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.
I have reported in respect of the examination of the Charity’s accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.
## _**Independent Examiner’s Statement**_
The Charity’s gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.
I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:
- the accounting records were not kept in accordance with section 130 of the Charities Act
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a ‘true and fair’ view which is not a matter considered as part of an independent examination.
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Mr M J Forshaw BA FCA Haines Watts Pacific Chambers 11-13 Victoria Street Liverpool L2 5QQ
Page 7
## **NEUROBLASTOMA UK**
## **STATEMENT OF FINANCIAL ACTIVITIES**
## **YEAR ENDED 31 DECEMBER, 2022**
|
Note
**INCOME AND ENDOWMENTS FROM:**
Donations
2
Other trading activities
3
Income from investments
4
**_TOTAL_**
**EXPENDITURE ON:**
Raising funds
5
**Charitable activities:**
Grants payable and grant amendments
6
Governance costs
7
**_TOTAL_**
**_NET (EXPENDITURE)/INCOME_**
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
**_TOTAL FUNDS CARRIED FORWARD_**|Unrestricted Funds
31 December, 2022
£
£
250,365
9,339
8,712
**268,417**
(7,506)
(691,520)
(119,754)
**(818,780)**
**(550,363)**
622,554
**72,191**|Unrestricted Funds
31 December, 2022
£
£
250,365
9,339
8,712
**268,417**
(7,506)
(691,520)
(119,754)
**(818,780)**
**(550,363)**
622,554
**72,191**|Unrestricted Funds
31 December, 2021
£
£
387,955
29,238
130
417,323
(7,996)
(9,333)
(104,354)
(121,683)
295,640
326,914
622,554|Unrestricted Funds
31 December, 2021
£
£
387,955
29,238
130
417,323
(7,996)
(9,333)
(104,354)
(121,683)
295,640
326,914
622,554|
|---|---|---|---|---|
|||**268,417**
**(818,780)**||417,323
(121,683)|
||||||
|||**(550,363)**
622,554||295,640
326,914|
|||**72,191**||622,554|
Page 8
## **NEUROBLASTOMA UK**
## **BALANCE SHEET**
## **AS AT 31 DECEMBER, 2022**
|Note
**CURRENT ASSETS**
Debtors and advance payments
9
Investments
10
Cash at bank
11
**_TOTAL CURRENT ASSETS_**
CREDITORS: Amounts falling due due within
one year
12
**_NET CURRENT ASSETS_**
CREDITORS: Amounts falling due in more
than one year
13,14
**_NET ASSETS_**
FUNDS OF THE CHARITY
Unrestricted fund
15|2022
2021
£
£
55,176
20,515
845,713
959,763
275,392
362,384|
|---|---|
||**1,176,281**
1,342,662|
||(605,785)
(480,230)|
||570,496
862,432
(498,305)
(239,877)|
||**72,191**
622,554|
||**72,191**
622,554|
The financial statements set out on pages 8 – 13 were approved by the Trustees on
TRUSTEE – Mr T Heddon
TRUSTEE – Mr M Dean
Page 9
**NEUROBLASTOMA UK**
## **NOTES TO THE ACCOUNTS**
## **YEAR ENDED 31 DECEMBER, 2022**
## **1. ACCOUNTING POLICIES**
## **Basis of preparing the financial statements**
The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)’, the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.
## **Donations**
Cash donations and gifts are included in full in the Statement of Fiinancial Activities when they are received by the charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees’ estimation of their market value when received.
## **Income from investments**
Investment income is included in the Statement of Financial Activities on an accruals basis.
## **Research Grant Awards**
These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.
## **Fund accounting**
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund Is included in the notes to the financial statements.
## **Cash Flow Statements**
The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.
## **Taxation**
The charity is exempt from Taxation on its charitable activities.
## **VAT**
As a non-trading organisation the charity is not registered for VAT purposes, and is unable to recover VAT incurred on its expenditure.
Page 10
## **NEUROBLASTOMA UK**
||**NEUROBLASTOMA UK**|**NEUROBLASTOMA UK**||
|---|---|---|---|
||**NOTES TO THE ACCOUNTS (Continued)**|||
||**YEAR ENDED 31 DECEMBER, 2022**|||
|**2.**|**DONATIONS**|||
|||2022|2021|
|||£|£|
||Donations and fund-raising|250,365|387,955|
|3.|**OTHER TRADING ACTIVITIES**|||
|||2022
|2021|
|||£
|£|
||Job Retention Scheme grant||750|
||Christmas cards, webshop and other income|9,339|28,488|
|||9,339|29,238|
|4.|**INCOME FROM INVESTMENTS**|||
|||2022
|2021|
|||£|£|
||COIF deposit|5,949
|72|
||National savings income bonds|2,763
|58|
|||8,712
|130|
|5.|**EXPENDITURE ON RAISING FUNDS**|||
|||2022
|2021|
|||£|£|
||Fund-raising and publicity costs
|7,506|7,996|
|6.|**GRANTS PAYABLE AND GRANT AMENDMENTS**|||
|||2022|2021|
|||£|£|
||University of Birmingham||4,981|
||Gaze
|214,385||
||Chesler|469,093||
||Ewing & Gao|10,000||
||Conferences, Travel and Other Grants||9,333|
||Write back|(1,958)
|(4,981)|
|||691,520
|9,333|
|7.|**EXPENDITURE ON CHARITABLE ACTIVITIES**|||
||Page 11|||
|Rent and facilities
Staff salaries and pension contributions
Staff training
Sporting event costs
Subscriptions
Travel
Computers, software and equipment hire
40thAnniversary celebration
Accounts and audit
Trustees meeting costs
Printing, postage and stationery
Sundries
Advertising and website
Insurance
Bank and professional charges
Seminar costs|2022
£
2021
£
8,923
11,163
67,118
66,767
0 435
8,566 902
2,183
1,622
177
78
5,195
2,905
11,792
0
5,556
10,872
0
0
1,456
604
1,727
804
5,870
6,633
1,119
977
72
592
0
0
119,754
104,354|
|---|---|
## 8. **TRUSTEES’ REMUNERATION AND BENEFITS**
There was no trustees’ remuneration or other benefits for the year ended 31 December, 2022 (2021 £NIL).
The Trust owns no premises.
9. **DEBTORS AND PREPAYMENTS**
|Receivables
Prepayments
Co-funding income
10.
**CURRENT INVESTMENTS**
COIF Deposit Fund
National Savings – Income bonds|2022
2021
£
£
1,188
1,188
23,238
6,827
30,750
12,500|
|---|---|
||55,176
20,515|
||2022
2021
£
£
495,713
609,763
350,000
350,000|
||845,713
959,763|
Page 12
**NEUROBLASTOMA UK**
## **NOTES TO THE ACCOUNTS (Continued)**
## **YEAR ENDED 31 DECEMBER, 2022**
|11.
**CASH AT BANK AND IN HAND**
Cash at Bank
12.
**CREDITORS – DUE WITHIN ONE YEAR**
Grant commitments
Trade creditors
Accruals
Co-funding income received in advance
13.
**CREDITORS – DUE IN MORE THAN ONE YEAR**
Grant commitments
14.
**GRANT COMMITMENTS**
Total commitments at 1 January, 2022
Paid in the year
New commitments
Written back in the year|2022
2021
£
£
275,392
362,384
2022
2021
£ £
562,130
442,311
27,755
22,019
900
900
15,000
15,000
605,785
480,230
2022
2021
£
£
498,305
239,877
2022
2021
£
£
682,189
1,001,604
(298,275)
(319,415)
678,478
4,981
(2)
(4,981)|
|---|---|
||1,062,391
682,189|
All of the grants paid in 2022 and 2021 were to institutions and to commission research studies. All of the new grant commitments in 2022 were to institutions.
## 15. **ANALYSIS OF UNRESTRICTED FUND**
|At 1 January, 2022
Net movement in funds for the year|2022
2021
£
£
622,554
326,914
(550,363)
295,640|
|---|---|
||72,191
622,554|
Page 13
Page 14